Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation

Thrombosis and Haemostasis

Volumn 87, Issue 2, 2002, Pages 199-205

  Kemmeren, J M ^a   Algra, A ^a   Meijers, J C M ^a   Bouma, B N ^a   Grobbee, D E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Coagulation; Desogestrel; Factor V Leiden; Levonorgestrel; Oral contraceptives

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PEPTIDE FRAGMENT; PROTHROMBIN;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; MENSTRUAL CYCLE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0036166757     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612973     Document Type: Article

References (34)

1. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs
2. Risks and mechanisms of cardiovascular events in users of oral contraceptives
3. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study
4. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
5. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
6. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women
7. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
8. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
9. First-time use of newer oral contraceptives and the risk of venous thromboembolism
10. The changing scene - An unnecessary pill crisis
11. The aftermath of a pill scare: Regression to reassurance
12. Effect of oral contraceptives on haemostasis variables
13. Effects on haemostasis variables by second and third generation combined oral contraceptives: A review of directly comparative studies
14. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: A review
15. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS)
16. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study
17. Venous thrombosis: A multicausal disease
18. Low-dose combined oral contraceptives
19. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
20. Oral contraceptives and venous thromboembolic disease: The effect of the oestrogen dose
21. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V
22. Renewed interest in haemostasis changes induced by oral contraceptives (OCs)
23. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
24. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways
25. Effect of second and third generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation
26. Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels
27. The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids
28. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults
29. Plasma lipoproteins enhance tissue factor-independent factor VII activation
30. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa
31. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: Influence of the factor VR506Q mutation
32. Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa-factor IXa complex - Species specific interactions of components of the protein C anticoagulant system
33. Factor V antigen levels and venous thrombosis: Risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels
34. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation